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Available online 20 December 2018Background: Endemic Burkitt lymphoma (eBL) is an aggressive childhood B-cell lymphoma linked to Plasmodium
falciparum (Pf) malaria in sub-Saharan Africa. We investigated antibody reactivity to several human receptor-
binding domains of the Pf erythrocytemembrane protein 1 (PfEMP1) that play a key role inmalaria pathogenesis
and are targets of acquired immunity to malaria.
Methods: Serum/plasma IgG antibody reactivity was measured to 22 Pf antigens, including 18 to PfEMP1 CIDR
domains between cases and controls from two populations (149 eBL cases and 150 controls from Ghana and
194 eBL cases and 600 controls from Uganda). Adjusted odds ratios (aORs) for case-control associations were
estimated by logistic regression.
Findings: There was stronger reactivity to the severe malaria associated CIDRα1 domains than other CIDR do-
mains both in cases and controls. eBL cases reacted to fewer antigens than controls (Ghana: p = 0·001;
Uganda: p = 0·03), with statistically signiﬁcant lower ORs associated with reactivity to 13+ antigens in
Ghana (aOR 0·39, 95% CI 0·24–0·63; pheterogeneity = 0·00011) and Uganda (aOR 0·60, 95% CI 0.41–0·88;
pheterogeneity = 0·008). eBL was inversely associated with reactivity, coded as quartiles, to group A variant
CIDRδ1 (ptrend = 0·035) in Ghana and group B CD36-binding variants CIDRα2·2 (ptrend = 0·006) and
CIDRα2·4 (ptrend = 0·033) in Uganda, and positively associated with reactivity to SERA5 in Ghana (ptrend =
0·017) and Uganda (ptrend = 0·007) and group A CIDRα1·5 variant in Uganda only (ptrend = 0·034).
Interpretation: eBL cases reacted to fewer antigens than controls using samples from two populations, Ghana and
Uganda. Attenuated humoral immunity to Pf EMP1 may contribute to susceptibility to low-grade malaria and
eBL risk.
Funding: Intramural Research Program, National Cancer Institute and National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Department of Health and Human Services.m. 6E118 MSC 9706, Bethesda,
ye).
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AfricaD lic1. IntroductionBurkitt lymphoma (BL) is an aggressive B-cell lymphoma character-
ized by chromosomal translocation involving c-MYC oncogene and
immunoglobulin gene regions [1]. An endemic form of BL (eBL) occursense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
EndemicBurkitt lymphoma (eBL) is a germinal centre B-cell tumour
that was described in African children N50 years ago and linked to
Plasmodium falciparum (Pf) malaria infection because of similar
geographical distributions. This association was confirmed in
studies measuring IgG reactivity to malaria schizont antigens.
However, those results provided limited insights about malaria-
related immunological predisposition because themalaria schizont
antigens tested are not known to play a role in protective immunity
against malaria. Immunity to malaria is thought to be mediated
through acquisition of antibodies targeting and inhibiting human
receptor binding by the highly polymorphic malarial Pf erythrocyte
membrane protein 1 (PfEMP1). PfEMP1 is exported to the erythro-
cyte surfacewhere it binds endothelial receptors, thereby allowing
the parasites to escape blood circulation and destruction in the
spleen. To escape immune detection, the PfEMP1 protein family
has diversified into four main types of PfEMP1: VAR2CSA
PfEMP1, expressed by parasites binding chondroitin sulphate A
in the placenta; and three types of PfEMP1 characterized by pres-
ence either a CIDRα1, CIDRα2–6 or CIDRβ/δ/γ domains that bind
to EPCR, CD36 or an unknown receptor, respectively, in endothe-
lial tissues. Infection with parasites expressing EPCR-binding
PfEMP1 is associated with severe malaria, whereas acquisition
of antibodies to CIDRα1 correlates with development of immunity
to severemalaria.We searched PUBMEDwith terms (“Burkitt lym-
phoma” AND “malaria”) to identify studies that have evaluated im-
mune responses to PfEMP1 antigens in relation to eBL. We found
only two papers that reported some data about IgG reactivity to
PfEMP1 antigens in eBL cases and controls. One study tested
two PfEMP1 antigens (DBL-α and VAR2CSA) as part of a 15-
malaria antibody Luminex panel, while the other study focused
only on reactivity to VAR2CSA. Thus, the relationship between
eBL and IgG reactivity to PfEMP1 antigens, which represent the
main functional diversification of PfEMP1 and mediate severe
childhood malaria, remains open for investigation.
Added value of this study
We report the first quantitative and qualitative relationships be-
tween eBL and IgG reactivity to 13PfEMP1 and 3 non-PfEMP1 an-
tigens reliably tested using case-control data from Ghana and
Uganda.We observed lower IgG reactivity to 13 PfEMP1 antigens
in eBL cases compared to controls—0·39-fold in Ghana and 0·60-
fold in Uganda. These results are not readily explained by selection
bias, confounding or reverse causality, as eBL is associated with
elevated IgG reactivity to other antigens, particularly Epstein-
Barr virus. Our study highlights the potential to untangle the pre-
disposition to eBL through study of immune responses to malaria
antigens that play a central role in pathogenesis of severe malaria.
Implications of all the available evidence
Endemic BL develops in a small fraction of children 4–6 years after
the general peak age of severemalaria. Our findings of a pattern of
attenuated IgG reactivity to PfEMP1 antigens in eBL children than
controls prompt two opposing questions: a) does clinical eBL de-
crease reactivity to PfEMP1 antigens and, if so, do children with
eBL become more susceptible to malaria infection? or b) is the at-
tenuated reactivity to PfEMP1 antigens a pattern that precedes
eBL and predisposes to recurrent low-grade malaria and eBL risk
in malaria-exposed children. Further research focused on eBL
cases and children exposed to heavymalariamayuncover a profile
of susceptibility to severe malaria or a profile of attenuated IgG re-
activity pattern associated with resistance to severe malaria but
susceptibility to recurrent low-grade malaria and eBL risk.
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similar distribution of eBL with Plasmodium falciparum (Pf)malaria in-
fection suggested etiological linkage [3]. A Mendelian randomization
analysis using the sickle cell trait as an instrumental variable supported
a causal role of malaria in eBL [4]. Pf infection increases eBL risk by stim-
ulating polyclonal expansion of B-cells, including those with chromo-
somal translocations [1].
Although Pf causes lethal severe malaria, starting at a median age of
10 months with a peak in children aged 2–3 years old [5], the relation-
ship between immunity to malaria and eBL, which occurs 4–6 years
after the peak age of severe malaria, is poorly deﬁned. Severe malaria
pathogenesis is closely tied to Pfparasite's capacity to sequester infected
red blood cells (iRBCs) to the endothelium of the microvasculature [6].
This sequestration allows iRBCs to escape destruction in the spleen
and is mediated by Pf erythrocyte membrane protein 1 (PfEMP1)
binding to the host endothelial receptors. PfEMP1-derived antigens
are targets of acquired immunity to malaria [6], and as a result, the
PfEMP1-encoding var genes have expanded to ~60 different var genes,
bestowing each parasite a similar repertoire of PfEMP1 phenotypes.
PfEMP1s have diversiﬁed to four mutually exclusive adhesion pheno-
types, associated with different complications of malaria: parasites
expressing VAR2CSA PfEMP1 cause pregnancy-associated malaria by
binding placental chondroitin sulfate A (CSA) [7]; CIDRα1 domain-
containing PfEMP1 bind to endothelial protein C receptor (EPCR) [8]
and are expressed by parasites causing severe malaria [9]; PfEMP1
with CIDRα2–6 domains bind the leukocyte differentiation antigen
(CD36) [10] and are frequently detected in parasites causing mild or
asymptomatic malaria infections [11]; and PfEMP1 with CIDRβ/δ/γ
domains bind unknown receptors but have not been associated with
any speciﬁc malaria complication. In addition to blood congestion and
local inﬂammation due to sequestration, parasites expressing the
EPCR-binding CIDRα1 type PfEMP1s are thought to aggravate patho-
genesis by inhibiting EPCR binding to activated protein C leading to dys-
functional regulation of inﬂammation, coagulation and endothelial cell
integrity [12].
Acquisition of anti-PfEMP1 antibodies also reﬂects the association of
EPCR-binding PfEMP1 with severe malaria, as individuals living in
malaria endemic areas acquire antibodies to CIDRα1 antigens before
antibodies to other CIDRα variants, i.e., early in life when risk of severe
malaria is highest [13]. Because eBL develops at a median age of
6–9 years, after the peak age for severe malaria [2], study of IgG reactiv-
ity to PfEMP1 subsets or to PfEMP1 in generalmay shed light on both the
nature of malaria immunity and eBL risk. We characterized the reper-
toire of IgG reactivity to 13 PfEMP1, as well as 3 non-PfEMP1 antigens
(Supplementary Table 1) reliably tested, and associations of this reper-
toire to eBL in children from Ghana and Uganda.
2. Materials and methods
2.1. Study design and participants
We analyzed archival serum/plasma samples from 150 eBL
cases and 150 eBL-free controls aged 0–15 years from Ghana
(enrolled1965–1994) [14] and 194 eBL cases and 600 eBL-free controls
from Uganda (enrolled 2010–2015) exposed to malaria from birth [4].
The Ghana cases were enrolled at Korle Bu Hospital in Accra and the
controls were enrolled contemporaneously from the same village as
the cases [14]. Age, sex, and date of enrollment of participants were
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separation tubes and serum aliquots were prepared and stored at
−70 °C until testing [15]. The Uganda cases and controls were from
the Epidemiology of Burkitt Lymphoma in East African Children and
Minors (EMBLEM) in malaria and eBL endemic regions of Northern
Uganda [4,16]. The eBL cases were enrolled at two hospitals with facil-
ities to diagnose and treat eBL in Northern Uganda (St. Mary's Hospi-
tal, Lacor, in Gulu, and Kuluva Hospital in Arua district). Awareness
messages about eBL were dissemnated to increase case spotting and
referral and diagnosis and treatment of eBL. The controls were healthy
children in the same age range as the eBL cases enrolled from 100 ran-
dom villages in the study area, as described previously [16]. Cases and
controls were regular residents of Northern Uganda (at least 4 months
prior to enrollment). The season of enrollment and the rural or urban
status or proximity to water of the village was captured to enable ad-
justment for unmeasured factors correlated with climatic or micro-
geographical factors [16].
Age, sex, address, and detailed information about lifetime inpatient
or outpatient malaria treatment (never, 0–12 months, or N13 months
ago) and other household exposures were captured using structured
questionnaires administered to both cases and controls. Pre-treatment
venous blood specimens were collected in EDTA tubes for research
(10 ml) and clinical tests (4 ml). Clinical specimens were immediately
tested for malaria using microscopy and malaria-rapid diagnostic tests
(malaria-RDTs) [16]. Research specimens were transported in cold
boxes to ﬁeld laboratories within two hours of collection, and centri-
fuged for 15 min at 1300g to separate plasma, buffy coat, and red cell
fractions and stored at−80 °C.
2.2. Ethical issues
The Ofﬁce of Human Subject Research at the National Institutes of
Health gave ethical approval to study the anonymized Ghana samples.
Ethical approval for the EMBLEM study was given by the Uganda Virus
Research Institute Research Ethics Committee, the Uganda National
Council for Science and Technology, and the National Cancer Institute
Special Studies Institutional Review Board. Written informed consent
was obtained from the child's parents and assent from children aged
≥7 years old.
2.3. Laboratory procedures
IgG reactivity to 22 Pf-derived recombinant antigens was measured
in previously unthawed or minimally thawed serum/plasma samples
by a multiplex Luminex bead assay. Tetanus toxoid and bovine serum
albumin (BSA) antigens were included in the assay to assess non-
malaria-related reactivity. The Pf antigens included 18 functional but ge-
netically diverse 3D7 PfEMP1 CIDR domains [8] and 4 non-PfEMP1 pro-
teins (Supplementary Table 1: glutamate-rich protein (GLURP), 6NANP
protein, SE36, a recombinant antigen of serine repeat antigen5 (SERA5),
and histidine richprotein-2 (HRP-2)) [14]. The selected PfEMP1 variants
represent the functional and sequence diversiﬁcation of PfEMP1, includ-
ing 9 EPCR-binding phenotype CIDRα1 domains with antigens
representing all sequence sub-groups CIDRα1–1·8 domain classes; 6
group B CD36-binding phenotype CIDRα2·2–3·3 domains; and 3
CIDRδ1 domains with unknown receptor binding phenotype. The CIDR
proteins were produced in a Baculovirus expression system and func-
tionally validated for receptor binding as previously described
[10,17,18].
Each protein was covalently coupled to particular ﬂuorescence-
coded, carboxylated Luminex microspheres (beads) according to the
manufacturer's protocol [17]. Before multiplexing the assay, antigen-
bead coupling was validated using standard control serum and Tag-
speciﬁc antibodies. IgG reactivity of each sample to each antigen was
measured using a 96-well plate format Luminex instrument, mixingbeads and plasma diluted 1:80 in Assay Buffer E (ABE; 0.1% BSA, 0.05%
Tween-20, 0.05% sodium azide in PBS, pH 7.4) as previously described
[17].
Standard reference sera from 40 malaria-naïve individuals from
Denmark (DK controls) were included in all runs. IgG reactivity per an-
tigen was reported as median ﬂuorescent intensity (MFI) readings for
100 read beads. Blinded quality control (QC) duplicate samples from
25 Ghanaian children were included to assess variability within and be-
tweenplates. The case-control andQC status and the country of origin of
the samples were masked during testing.2.4. Statistical analysis
Intra-class correlation coefﬁcients (ICCs) of MFI values were calcu-
lated using 24 of 25 successfully tested technical replicates. Antigens
with ICCs N70% were included in the analyses. Results for 5 PfEMP1 an-
tigenswith ICCs b70% (Supplementary Table 1) and for HRP-2 (total of 6
antigens), whose reactivity in the cases and controls was lower than in
the DK controls, were excluded from further analysis. MFI values for the
remaining 16 antigens (13 PfEMP1 and 3 non-PfEMP1) were trans-
formed using the natural logarithm before analysis. The threshold of re-
activity for each antigen was deﬁned separately for Ghana and Uganda
samples using two methods: a) the mean+ 2 times the standard devi-
ation of the DK controls [17]; and b) using a ﬂexible two-component
mixture models [19] ﬁtted to the MFI values from the controls and the
BL-free controls for the respective country. This model assumes that
theMFI values for each antigen reﬂect distributions from two subpopu-
lations with distinct malaria infection experience, but makes no as-
sumptions about normality of the distributions, and maximizes the
sum of sensitivity and speciﬁcity of the threshold [19]. The models for
SE36 did not converge for the Uganda data so the threshold obtained
from the Ghana data was used for the Ugandan samples. The two
methods yielded similar patterns except for six antigens (Supplemen-
tary Table 2), whose model-determined IgG threshold resulted in a
prevalence 30–50% higher than that determined by the SD-based
method in one or both populations. Model-determined results were
considered more realistic for children from these populations, who
have been exposed to malaria since birth, and are presented hereafter.
The Ghana and Uganda studies were analyzed separately. IgG reac-
tivity according to basic epidemiological variables was veriﬁed sepa-
rately for cases and controls (results for the controls only are
presented: Supplementary Tables 3 and 4). These conﬁrmed no sex dif-
ferences but higher reactivity with older age, with malaria antigenemia
(anti-HRP-2 antibodies inGhana [14] andRDT inUganda [16], andwith-
out the sickle cell trait in Uganda and Ghana [4]. Chi-squared tests were
used to assess differences in reactivity for categorical variables. Odds ra-
tios (ORs) and 95% conﬁdence intervals (CIs) for case-control associa-
tions were calculated using logistic regression models with IgG
reactivity to malaria antigens coded as a binary variable, as quartiles
based on cutoffs determined from the controls, or breadth of reactivity
(number of antigens with reactivity above threshold). The basic models
were adjusted for age group and year of enrollment for Ghana, and for
age group, proximity of village to surface water (near/far), rural/urban
status of village [16], and assay plate number for Uganda. We assessed
independent effects by including all the antigens with either a marginal
two-sided p-value for heterogeneity or trend b 0·05 in the same logistic
model. For the given sample sizes the study had 80% power to detect an
OR of 2.4 for the highest compared to the lowest quartiles of IgG reactiv-
ity with an alpha level of 0.05 in Ghana and an OR of 1.9 for the highest
compared to the lowest quartile in Uganda. Because our studywas con-
ducted to generate hypotheses about the antibody reactivity against
PfEMP1 and selected non-PfEMP1 antigens with eBL, we did not for-
mally adjust for multiple comparisons. Two-sided p b 0·05 was consid-
ered statistically signiﬁcant.
Table 1
Characteristics of cases and controls in Ghana and the Uganda EMBLEM study.
Characteristics Ghana Uganda
Controls (%)a,b Cases (%)a p value Controls (%)a Cases (%)a p value
All subjects 149 150 600 194
Sex 1 0·222
Female 54 (36%) 55 (37%) 271 (45%) 76 (39%)
Male 95 (64%) 95 (63%) 329 (55%) 115 (59%)
Age group, years 0·759 0·731
‘0–2 5 (3%) 2 (1%) 33 (6%) 7 (4%)
‘3–5 26 (17%) 29 (19%) 73 (12%) 27 (14%)
‘6–8 54 (36%) 62 (41%) 162 (27%) 48 (25%)
‘9–11 43 (29%) 36 (24%) 191 (32%) 60 (31%)
‘12–14 13 (9%) 13 (9%) 129 (22%) 49 (25%)
15+ 8 (5%) 8 (5%) 12 (2%) 3 (2%)
Enrolment years 0·042
1965–1974 53 (36%) 46 (31%) – –
1975–1984 45 (30%) 66 (44%) – –
1985–1994 51 (34%) 38 (25%) – –
2010–2012 60 (10%) 104 (54%)
2013–2015 540 (90%) 90 (46%) b0·0001
Enrollment season b0·0001
Dry – – 443 (74%) 89 (46%)
Wet – – 157 (26%) 105 (54%)
Rural/urban 0·840
Rural – – 380 (63%) 115 (59%)
Urban – – 220 (37%) 70 (36%)
Proximity to surface water b0·0001
Near – – 166 (28%) 25 (13%)
Far – – 434 (72%) 160 (82%)
Region – 1
Northwest – – 134 (22%) 43 (22%)
North-central – – 466 (78%) 151 (78%)
Outpatient malaria b0·0001
In past 12 months – – 407 (68%) 88 (45%)
N12 months ago – – 55 (9%) 43 (22%)
No – – 134 (22%) 60 (31%)
Inpatient malaria – 0·0461
In past 12 months – – 83 (14%) 15 (8%)
N12 months ago – – 116 (19%) 47 (24%)
No 396 (66%) 129 (66%)
Malaria infection 1 b0·0001
Positive 102 (68%) 103 (69%) 330 (55%) 68 (35%)
Negative 47 (32%) 47 (31%) 270 (45%) 124 (64%)
Sickle cell genotype 0·013
AA – – 490 (82%) 166 (86%)
AS/SS – – 110 (18%) 19 (10%)
a Percentages do not add up to 100% for covariates missing data for certain categories.
b Quality control failed for IgG results from one control subject, so this subject was excluded from all analyses.
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3.1. Baseline characteristics of the study participants
As detailed in Table 1, the eBL cases and controls did not differ with
respect to sex, and age-group. Qualitatively, IgG reactivity seemed gen-
erally stronger in Ghana than in Uganda. IgG reactivity to tetanus toxoid
wasmuch lower in Ghana and Ugandan subjects than DK controls (MFI
range: 146–2286 versus 752–26,622), likely reﬂecting higher known
tetanus vaccination rates in DK controls compared to African children,
or perhaps malaria-related immunosuppression. In Uganda, more
caseswere enrolled during 2010–2012,whereasmost controlswere en-
rolled in 2013–2015 (pheterogeneity b 0·0001). Caseswere less likely to be
malaria-RDT positive at enrollment (p b 0·0001) and to have the sickle
cell trait (p= 0.013) [4].
3.2. IgG reactivity to PfEMP1-derived antigens in the control children
Among controls only, IgG reactivity to Pf-derived antigens was unre-
lated to sex but increased signiﬁcantlywith older age, was positively as-
sociated with malaria antigenemia, and was inversely associated with
carriage of the sickle cell trait (Supplementary Table 4). EPCR-bindingCIDRα1 antigens (associatedwith severemalaria)weremore often rec-
ognized than other CIDR variants. Although children who reported no
lifetime inpatient or outpatient malaria treatment may be considered
to have been exposed lightly or not at all, we found strong reactivity
against EPCR-binding PfEMP1 CIDRα1 antigens in the controls (Supple-
mentary Table 4), suggesting that these children in Ugandawere indeed
exposed to malaria and the sparseness of symptoms likely reﬂects anti-
disease immunity (capacity to tolerate parasite infections without de-
veloping a fever).
3.3. Association between eBL and IgG reactivity to PfEMP1-derived antigens
As detailed in Table 2, IgG reactivity to 11 of the PfEMP1-derived
antigens, and to the 6NANP antigen was lower in eBL cases com-
pared to controls in Ghana. Similarly, Ugandan eBL cases had lower
IgG reactivity to three PfEMP1-derived antigens, two of which
matched those found in Ghana. Consistently, signiﬁcant inverse asso-
ciations between eBL and IgG reactivity, as a binary variable, were
observed for all functional types of CIDR, suggesting that reduced
IgG reactivity in eBL is not linked to PfEMP1 function. As noted for
controls, cases also recognized CIDRα1 antigens (associated with se-
vere malaria) more commonly than other CIDR domain types. By
Table 2
Association between endemic Burkitt lymphoma and serum IgG reactivity to 16 P falciparummalaria antigens successfully tested in Ghana and Uganda EMBLEM study.
Domain Binding
phenotype
Antigen Ghana Uganda
% Controls
positivea
% Cases
positivea
OR (95% CI)b p
value
% Controls
positivea
% Cases
positivea
OR (95% CI)b p
value
CIDRα1·1 EPCR PfEMP1_IT4var06 83% 73% 0·53 (0·30–0·95) 0·031 81% 83% 1·00 (0·62–1·63) 0·987
CIDRα1·1 EPCR PfEMP1_raj116_var8 83% 71% 0·50 (0·28–0·89) 0·016 73% 75% 1·00 (0·65–1·54) 0·992
CIDRα1·8a EPCR PfEMP1_GA026 84% 73% 0·50 (0·28–0·90) 0·019 70% 70% 0·83 (0·55–1·25) 0·371
CIDRα1·6b EPCR PfEMP1_GA019 86% 73% 0·41 (0·22–0·76) 0·004 74% 78% 1·02 (0·66–1·56) 0·941
CIDRα1·5 EPCR PfEMP1_1965–2 82% 65% 0·39 (0·22–0·70) 0·001 65% 76% 1·68 (1·10–2·56) 0·014
CIDRδ Unknown PfEMP1_HB3var05 79% 60% 0·35 (0·20–0·60) 0·000 59% 59% 0·86 (0·60–1·25) 0·434
CIDRδ Unknown PfEMP1_IT4var02 86% 70% 0·36 (0·20–0·66) 0·001 72% 74% 0·96 (0·63–1·45) 0·836
CIDRα2·2 CD36 PfEMP1_IT4var24 81% 65% 0·45 (0·26–0·77) 0·003 78% 62% 0·41 (0·28–0·61) 0·000
CIDRα3·3 CD36 PfEMP1_IT4var26 80% 67% 0·52 (0·30–0·90) 0·018 76% 80% 1·20 (0·77–1·87) 0·418
CIDRα2·9 CD36 PfEMP1_IT4var30 77% 61% 0·48 (0·29–0·81) 0·006 73% 75% 0·99 (0·65–1·51) 0·955
CIDRα2·4 CD36 PfEMP1_IT4var33 79% 65% 0·55 (0·32–0·93) 0·026 68% 60% 0·59 (0·40–0·85) 0·006
CIDRα2·9 CD36 PfEMP1_IT4var45 77% 65% 0·59 (0·35–1·00) 0·051 71% 71% 0·81 (0·54–1·20) 0·297
CIDRα2·9 CD36 PfEMP1_IT4var61 79% 69% 0·59 (0·34–1·02) 0·056 70% 74% 1·14 (0·75–1·73) 0·544
non-PfEMP1 – GLURP_R2 79% 79% 1·06 (0·59–1·88) 0·850 54% 50% 0·70 (0·49–1·00) 0·050
non-PfEMP1 – SE36 47% 56% 1·60 (0·99–2·59) 0·053 20% 24% 1·24 (0·82–1·86) 0·310
non-PfEMP1 – 6NANP 75% 59% 0·47 (0·28–0·78) 0·003 69% 70% 0·90 (0·60–1·36) 0·626
No of antigens with reactivityc
0–7 15% 23% Ref 22% 19% Ref ·
8–12 19% 35% 1·07 (0·52–2·22) 0·856 32% 44% 1·37 (0·83–2·27) 0·215
13–15 40% 23% 0·34 (0·17–0·69) 0·003 39% 31% 0·76 (0·44–1·31) 0·322
15+ 26% 19% 0·51 (0·24–1·09) 0·083 6% 6% 0·83 (0·35–1·95) 0·667
X2 trend (P-value) 0·71 (0·56–0·90) 0·004 0·83 (0·66–1·04) 0·108
X2 Heterogeneity (3df) 0·001 0·034
IgG reactivity to 13+ antigens d 66% 42% 0·39 (0·24–0·63) 0·000 45% 37% 0·60 (0·41–0·88) 0·008
a IgG reactivity deﬁned as being above the MFI threshold from the mixture model (See Methods) · Results for 5 antigens (PfEMP1_1994–2, PfEMP1_HB3var03, PfEMP1_IT4var22,
PfEMP1_2083–1, PfEMP1_HB3var35, and HRP-2) that had low reliability results or were unexpectedly low were excluded from analysis (See Methods).
b Case-control associationswith IgG reactivitywere determined using logistic regressionmodels, controlling for age group and calendar year enrollment period inGhana and age group,
proximity to water, rural urban status, and plate number in Uganda· Chi-square results are provided assuming linear relationship across categories, based on quartiles of MFI values, or
heterogeneity of associations across the quartiles (See Methods).
c The groupings for the numbers of antigens with reactivity above threshold were determined to assess trends.
d The grouping of the numbers of antigens with reactivity above threshold was chosen to assess effects among highly reactive children.
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eBL and IgG reactivity to group A EPCR-binding variant CIDRα1·5,
being inverse in Ghana (OR = 0·39, 95% CI 0·22–0·70; pheterogeneity
= 0·0012) and positive in Uganda (OR = 1·68, 95% CI 1·10–2·56;
pheterogeneity = 0·014). IgG reactivity to GLURP was the most intense,
but it was not associated with eBL.
The overall breadth of IgG reactivity to the antigenswas lower in the
eBL cases than controls in Ghana (pheterogeneity = 0·001) and in Uganda
(pheterogeneity = 0·034) (Table 2). IgG reactivity to 13 or more antigens
(median among all children) was inversely associated with eBL in
Ghana (OR 0·39, 95% CI 0·24–0·63; pheterogeneity = 0·0011) and in
Uganda (OR 0·60, 95% CI 0·41–0·88; pheterogeneity = 0·008). Breadth
of IgG reactivity was also decreased within groups of CIDR antigens
representing EPCR-, or CD36-, or unknown-binding phenotypes in
Ghana (CIDRα1: aOR = 0·30, 95% CI 0·14–0·63; pheterogeneity =
0·0011; and CIDRα2·2–2·9: aOR = 0·35, 95% CI 0·17–0·70;
Pheterogeneity = 0·0025; and CIDRδ: aOR = 0·28, 95% CI 0.14–0·53;
pheterogeneity ≤0·0001, respectively), and with a similar trend for the
CD36-binding-phenotypes in Uganda (CIDRα2·2–2·9: aOR = 0·59,
95% CI 0·33–1·06; pheterogeneity = 0·077). Reactivity to SE36 was posi-
tively associatedwith eBL in Ghana (ptrend= 0·017) andUganda (ptrend
= 0·007).
Finally, in models that included all antigens with univariate eBL
associations (13 CIDR types and 2 non-PfEMP1 in Ghana, four
CIDR antigens and 2 non-PfEMP1 in Uganda; Tables 3 and 4, last
columns), IgG reactivity level, coded as quartiles of MFI, against 14
antigens, including all evaluated CIDR types in Ghana and three an-
tigens in Uganda, was inversely associated with eBL. However, we
also found positive associations between eBL and IgG reactivity to
one antigen in Ghana (Table 3) and two antigens in Uganda
(Table 4), but with no speciﬁc association to functional CIDR do-
main type.4. Discussion
We investigated the breadth and intensity of IgG reactivity to 13
PfEMP1- and 3 non-PfEMP1-derived antigens reliably tested in children
with eBL and similar-age, geographically-matched healthy controls ex-
posed tomalaria frombirth in Ghana andUganda. Serum from eBL cases
and controlsmore often reacted on the PfEMP1 CIDRα1 domains associ-
ated with severe malaria. Counterintuitively, compared to controls,
serum from eBL cases in both Ghana and Uganda showed lower breadth
and intensity of IgG reactivity to PfEMP1 CIDR domains. This ﬁnding
mirrors our previous observation of decreased IgG reactivity to
VAR2CSA in a different set of samples from the Ghana study [20]. The
lower breadth and intensity of IgG reactivity to PfEMP1-derived anti-
gens affected all PfEMP1 functional domain types in Ghana and
Uganda; thus, the reduced IgG reactivity is unrelated to PfEMP1 func-
tional phenotype. We hypothesize that the observed IgG hypo-
reactivity is a pattern that presents pre-eBL and this attenuated immu-
nity to malaria predisposes children to breakthrough Pf infections, with
eBL as a rare complication.
IgG antibodies to PfEMP1 are signiﬁcantly higher in patients with
uncomplicated malaria compared to those with severe malaria [21].
The reduced diversity of PfEMP1 antibodies in our eBL patients suggests
that these patients should become more susceptible to severe malaria.
However, eBL patients were less likely to have had inpatient or outpa-
tient malaria in the past year, thus the attenuated IgG reactivity to
fMP1 antigens is not associated with increased risk of severe malaria.
Risk of severe malaria is not known to be increased in eBL children. Be-
cause children in eBL areas are continually exposed to malaria parasites
from birth, their low risk of development of severe malaria could mask
the fact that these young children are heavily exposed and maintain a
more chronic, but uncomplicated type of malaria with smoldering in-
ﬂammation [12]. This would be sufﬁcient to maintain a high B cell
Table 3
Association between endemic Burkitt lymphoma and IgG reactivity to P falciparummalaria antigens successfully tested in Ghana.
PfEMP group Domain class Binding phenotype PfEMP1 assay Ghana
Controls (%) Cases (%) OR (95% CI)a Adjusted OR (95% CI)b
A CIDRαCIDRα1·1 EPCR PfEMP1_IT4var06
Q1 24% 41% Ref· Ref·
Q2 25% 25% 0·60 (0·32–1·12) 0·80 (0·3–2·18)
Q3 25% 18% 0·44 (0·23–0·85) 0·76 (0·22–2·62)
Q4 26% 17% 0·37 (0·19–0·72) 0·41 (0·1–1·72)
X2trend (P-value) · · 0·001 0·232
X2Heterogeneity (3df) (P-value) · · 0·013 0·569
A CIDRαCIDRα1·1 EPCR PfEMP1_raj116_var8
Q1 24% 40% Ref· Ref·
Q2 25% 27% 0·65 (0·35–1·22) 1·13 (0·4–3·17)
Q3 25% 17% 0·39 (0·20–0·77) 0·86 (0·23–3·22)
Q4 26% 16% 0·37 (0·19–0·73) 0·9 (0·18–4·4)
X2 trend (P-value) · · 0·001 0·832
X2Heterogeneity (3df) (P-value) · · 0·008 0·956
A CIDRαCIDRα1·8a EPCR PfEMP1_GA026
Q1 24% 37% Ref· Ref·
Q2 25% 28% 0·67 (0·36–1·26) 1·1 (0·44–2·73)
Q3 25% 17% 0·45 (0·23–0·89) 1·6 (0·48–5·36)
Q4 26% 18% 0·46 (0·24–0·9) 2·14 (0·53–8·71)
X2 trend (P-value) · · 0·009 0·276
X2Heterogeneity (3df) (P-value) · · 0·055 0·717
A CIDRαCIDRα1·6b EPCR PfEMP1_GA019
Q1 24% 46% Ref· Ref·
Q2 25% 20% 0·41 (0·22–0·79) 0·8 (0·28–2·28)
Q3 25% 19% 0·41 (0·22–0·79) 0·69 (0·22–2·17)
Q4 26% 15% 0·29 (0·15–0·57) 0·55 (0·14–2·08)
X2trend (P-value) · · 0·000 0·373
X2Heterogeneity (3df) (P-value) · · 0·001 0·848
A CIDRαCIDRα1·5 EPCR PfEMP1_1965–2
Q1 24% 45% Ref· Ref·
Q2 25% 23% 0·48 (0·25–0·91) 0·57 (0·22–1·46)
Q3 25% 14% 0·27 (0·13–0·55) 0·42 (0·14–1·26)
Q4 26% 17% 0·33 (0·17–0·66) 0·66 (0·2–2·18)
X2 trend (P-value) · · 0·000 0·495
X2Heterogeneity (3df) (P-value) · · 0·001 0·410
A CIDRδ Unknown PfEMP1_HB3var05
Q1 24% 43% Ref· Ref·
Q2 25% 20% 0·42 (0·22–0·8) 0·46 (0·18–1·17)
Q3 25% 24% 0·48 (0·25–0·91) 0·63 (0·22–1·84)
Q4 26% 13% 0·24 (0·11–0·49) 0·22 (0·06–0·73)
X2 trend (P-value) · · 0·000 0·035
X2Heterogeneity (3df) (P-value) · · 0·001 0·047
A CIDRδ Unknown PfEMP1_IT4var02
Q1 24% 40% Ref· Ref·
Q2 25% 25% 0·60 (0·32–1·12) 1·09 (0·4–2·96)
Q3 25% 21% 0·49 (0·26–0·94) 0·86 (0·29–2·58)
Q4 26% 14% 0·31 (0·16–0·62) 0·85 (0·23–3·13)
X2 trend (P-value) · · 0·001 0·687
X2Heterogeneity (3df) (P-value) · · 0·007 0·951
B CIDRα2·2 CD36 PfEMP1_IT4var24
Q1 24% 37% Ref· Ref·
Q2 25% 20% 0·51 (0·26–0·98) 0·52 (0·19–1·41)
Q3 25% 29% 0·83 (0·45–1·55) 2·76 (0·8–9·52)
Q4 26% 15% 0·38 (0·19–0·75) 1·04 (0·23–4·8)
X2 trend (P-value) · · 0·029 0·455
X2Heterogeneity (3df) (P-value) · · 0·019 0·006
B CIDRα3·3 CD36 PfEMP1_IT4var26
Q1 24% 40% Ref· Ref·
Q2 25% 27% 0·64 (0·35–1·2) 1·44 (0·53–3·95)
Q3 25% 14% 0·34 (0·17–0·68) 0·46 (0·15–1·46)
Q4 26% 19% 0·47 (0·24–0·9) 0·79 (0·24–2·58)
X2 trend (P-value) · · 0·006 0·328
X2Heterogeneity (3df) (P-value) · · 0·013 0·137
B CIDRα2·9 PfEMP1_IT4var30
Q1 24% 39% Ref· Ref·
Q2 25% 27% 0·63 (0·34–1·18) 0·88 (0·32–2·37)
Q3 25% 17% 0·44 (0·23–0·87) 1·12 (0·36–3·46)
Q4 26% 16% 0·40 (0·20–0·78) 0·93 (0·27–3·22)
X2 trend (P-value) · · 0·003 0·976
X2Heterogeneity (3df) (P-value) · · 0·025 0·958
B CIDRα2·4 CD36 PfEMP1_IT4var33
Q1 24% 43% Ref· Ref·
Q2 25% 26% 0·65 (0·35–1·2) 0·52 (0·18–1·45)
(continued on next page)
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Table 3 (continued)
PfEMP group Domain class Binding phenotype PfEMP1 assay Ghana
Controls (%) Cases (%) OR (95% CI)a Adjusted OR (95% CI)b
Q3 25% 14% 0·35 (0·17–0·69) 0·25 (0·07–0·89)
Q4 26% 17% 0·41 (0·21–0·8) 0·75 (0·17–3·41)
X2 trend (P-value) · · 0·002 0·481
X2Heterogeneity (3df) (P-value) · · 0·008 0·057
B CIDRα2·9 CD36 PfEMP1_IT4var45
Q1 24% 35% Ref· Ref·
Q2 25% 28% 0·79 (0·42–1·49) 1·35 (0·43–4·27)
Q3 25% 23% 0·69 (0·36–1·32) 2·4 (0·62–9·3)
Q4 26% 13% 0·38 (0·19–0·78) 1·06 (0·21–5·43)
X2 trend (P-value) · · 0·010 0·779
X2Heterogeneity (3df) (P-value) · · 0·059 0·313
B CIDRα2·9 CD36 PfEMP1_IT4var61
Q1 24% 38% Ref· Ref·
Q2 25% 29% 0·75 (0·41–1·4) 0·86 (0·32–2·34)
Q3 25% 18% 0·45 (0·23–0·88) 1·07 (0·34–3·37)
Q4 26% 15% 0·43 (0·21–0·85) 0·97 (0·24–3·86)
X2 trend (P-value) · · 0·004 0·911
X2Heterogeneity (3df) (P-value) · · 0·034 0·966
– – – GLURP_R2
Q1 24% 23% Ref· –
Q2 25% 33% 1·44 (0·75–2·76) –
Q3 25% 18% 0·70 (0·34–1·43) –
Q4 26% 26% 1·09 (0·56–2·13) –
X2 trend (P-value) · · 0·677 –
X2Heterogeneity (3df) (P-value) · · 0·211 –
– – – SE36
Q1 24% 29% Ref· Ref·
Q2 25% 9% 0·31 (0·14–0·67) 0·30 (0·11–0·79)
Q3 25% 38% 1·43 (0·76–2·67) 2·31 (1·01–5·3)
Q4 26% 25% 0·92 (0·48–1·77) 1·77 (0·69–4·53)
X2 trend (P-value) · · 0·391 0·017
X2Heterogeneity (3df) (P-value) · · 0·001 0·000
– – – 6NANP
Q1 24% 39% Ref· Ref·
Q2 25% 27% 0·64 (0·34–1·19) 0·92 (0·32–2·69)
Q3 25% 18% 0·44 (0·23–0·86) 0·53 (0·15–1·86)
Q4 26% 16% 0·38 (0·19–0·76) 0·59 (0·16–2·12)
X2 trend (P-value) · · 0·002 0·342
X2Heterogeneity (3df) (P-value) · · 0·022 0·658
a Case-control associationswith IgG reactivity tomalaria antigens determined using logistic regression· IgG reactivity is coded as quartiles 0, 1, 2, and 3 estimated fromMFI values in the
country-speciﬁc controls, and the results are controlled for age group and calendar year enrollment period in Ghana (minimally adjusted models).
b Case-control associations with IgG reactivity to malaria antigens determined using logistic regression with additional adjustment for antigens associatedwith eBL at a p b 0·05 based
on trend or heterogeneity analysis in the minimally adjusted models.
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of proliferating B cells with primary deleterious IG-MYC translocations.
There is some evidence that PfEMP1 on infected iRBC membranes acti-
vates lytic EBV replication [22], a known carcinogen of eBL. However,
as outlined in a later paper from same authors [23], it was not clear
which PfEMP1 type was expressed by the parasites activating EBV, and
thus if the EBV activationwas speciﬁc to any speciﬁc type of PfEMP1. Re-
gardless of which actual protein is involved, EBV and Pf appear to syner-
gistically deregulate adenosine-induced cytosine deaminase (AICDA)
expression, which plays a key role in generating aberrant somatic
hypermutation to generate DNA changes that contribute to progression
of B-cells with IG-MYC translocations to eBL. Repeated cycles of
parasite-driven inﬂammation and germinal center reactions could also
lead to increased PD-1 expression on T follicular helper cells, a form of
T cell exhaustion [24]. This can lead to hyperproliferative B cell pheno-
types including hypergammaglobulinemia [25], a condition character-
ized by increased poly-speciﬁc IgG but lack of antigen-speciﬁc IgG,
probably due to defective formation of memory B cells [26]. Interest-
ingly, PD-1-dependent exhaustion of CD8+ T cells has been associated
with chronic malaria [24].
Because malaria is deadly and eBL occurs in older children, another
hypothesis is that eBL occurs in children who are more resistant to se-
vere malaria, possibly manifested by the attenuated IgG reactivity ob-
served in eBL children. We found a report on Tanzanian children
without eBL who never developed patent parasitemia during follow-up from birth [5]. These malaria-resistant children were similar to
those who were non-resistant for seroprevalence of sporozoite stage
antibody responses and, similar to our eBL cases, had lower IgG reactiv-
ity to three non-PfEMP1 antigens [5]. Our ﬁnding that eBL cases were
less likely to have malaria-antigenemia supports the idea that eBL
cases can control patent malaria. We found similar reports from a
study in Kenya [27] and a prospective study in Uganda [28], with results
being dismissed by the author's assumption that eBL cases were more
likely to have been treated with anti-malarial drugs prior to admission.
Our results are based on malaria-RDT, which remains positive for ap-
proximately 35–42 days after treatment of symptomatic malaria due
to persistent malaria antigenemia [29], and were supplemented by
questionnaires data, which show a lower frequency of inpatient and
outpatient malaria treatment in the cases one year before eBL onset.
The reduced diversity of PfEMP1 antibodies in malaria-resistant (or
eBL) children may be due to dysfunction in the T cell compartment as
a result of chronic malaria infection [24]. The reduced diversity of
PfEMP1 antibodies raises the question whether protection against ma-
laria disease in the eBL children is less dependent on antibodies. Those
children may have stronger immunity against liver stage Pf forms,
thereby reducing the load of liver-stage merozoites released into the
blood stream. Another possibility is that they utilize non-humoral
mechanisms to control blood-stage infection. Such mechanisms may
include soluble EPCR [12], CD36 on platelets [10], altered regulation of
cytokines released by Natural Killer (NK) cells [30], or γδ T cells [31].
Table 4
Association between endemic Burkitt lymphoma and IgG reactivity to P falciparummalaria antigens successfully tested in Uganda EMBLEM study.
PfEMP group Domain class Binding phenotype PfEMP1 assay Uganda
Controls (%) Cases (%) OR (95% CI)a Adjusted OR (95% CI)b
A CIDRαCIDRα1·1 EPCR PfEMP1_IT4var06
Q1 25% 24% Ref· –
Q2 25% 24% 0·86 (0·52–1·43) –
Q3 25% 27% 1·02 (0·62–1·67) –
Q4 25% 25% 0·91 (0·55–1·51) –
X2trend (P-value) · · 0·915 –
X2Heterogeneity (3df) (P-value) · · 0·893 –
A CIDRαCIDRα1·1 EPCR PfEMP1_raj116_var8
Q1 25% 23% Ref· –
Q2 25% 24% 0·97 (0·58–1·64) –
Q3 25% 26% 1·02 (0·6–1·73) –
Q4 25% 27% 1·15 (0·68–1·93) –
X2 trend (P-value) · · 0·540 –
X2Heterogeneity (3df) (P-value) · · 0·910 –
A CIDRαCIDRα1·8a EPCR PfEMP1_GA026
Q1 25% 24% Ref· –
Q2 25% 28% 1 (0·61–1·66) –
Q3 25% 24% 0·81 (0·48–1·38) –
Q4 25% 25% 0·83 (0·49–1·41) –
X2 trend (P-value) · · 0·363 –
X2Heterogeneity (3df) (P-value) · · 0·762 –
A CIDRαCIDRα1·6b EPCR PfEMP1_GA019
Q1 25% 22% Ref· –
Q2 25% 28% 1·05 (0·64–1·72) –
Q3 25% 29% 1·04 (0·62–1·73) –
Q4 25% 21% 0·8 (0·47–1·37) –
X2trend (P-value) · · 0·414 –
X2Heterogeneity (3df) (P-value) · · 0·686 –
A CIDRαCIDRα1·5 EPCR PfEMP1_1965–2
Q1 25% 12% Ref· Ref.
Q2 25% 40% 2·74 (1·56–4·8) 3·91 (2·08–7·34)
Q3 25% 25% 1·95 (1·07–3·54) 3·0 (1·5–6·01)
Q4 25% 23% 1·78 (0·96–3·28) 3·47 (1·63–7·36)
X2 trend (P-value) · · 0·544 0·034
X2Heterogeneity (3df) (P-value) · · 0·003 0·000
A CIDRδ Unknown PfEMP1_HB3var05
Q1 25% 23% Ref· –
Q2 25% 24% 1·04 (0·63–1·72) –
Q3 25% 28% 1·06 (0·64–1·76) –
Q4 25% 25% 0·91 (0·53–1·53) –
X2 trend (P-value) · · 0·731 –
X2Heterogeneity (3df) (P-value) · · 0·918 –
A CIDRδ Unknown PfEMP1_IT4var02
Q1 25% 22% Ref· –
Q2 25% 31% 1·18 (0·71–1·97) –
Q3 25% 25% 0·92 (0·54–1·58) –
Q4 25% 22% 0·86 (0·49–1·5) –
X2 trend (P-value) · · 0·349 –
X2Heterogeneity (3df) (P-value) · · 0·575 –
B CIDRα2·2 CD36 PfEMP1_IT4var24
Q1 25% 39% Ref· Ref.
Q2 25% 25% 0·58 (0·37–0·93) 0·58 (0·34–0·98)
Q3 25% 19% 0·42 (0·26–0·68) 0·48 (0·26–0·88)
Q4 25% 17% 0·37 (0·22–0·61) 0·38 (0·19–0·77)
X2 trend (P-value) · · 0·000 0·006
X2Heterogeneity (3df) (P-value) · · 0·000 0·038
B CIDRα3·3 CD36 PfEMP1_IT4var26
Q1 25% 20% Ref· –
Q2 25% 32% 1·55 (0·95–2·53) –
Q3 25% 22% 0·94 (0·55–1·61) –
Q4 25% 26% 1·1 (0·63–1·89) –
X2 trend (P-value) · · 0·698 –
X2Heterogeneity (3df) (P-value) · · 0·152 –
B CIDRα2·9 PfEMP1_IT4var30
Q1 25% 25% Ref· –
Q2 25% 22% 0·8 (0·48–1·33) –
Q3 25% 27% 0·93 (0·56–1·55) –
Q4 25% 26% 0·93 (0·55–1·56) –
X2 trend (P-value) · · 0·955 –
X2Heterogeneity (3df) (P-value) · · 0·847 –
B CIDRα2·4 CD36 PfEMP1_IT4var33
Q1 25% 34% Ref· Ref.
Q2 25% 25% 0·62 (0·39–1) 0·56 (0·31–1·01)
(continued on next page)
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Table 4 (continued)
PfEMP group Domain class Binding phenotype PfEMP1 assay Uganda
Controls (%) Cases (%) OR (95% CI)a Adjusted OR (95% CI)b
Q3 25% 24% 0·51 (0·31–0·84) 0·52 (0·26–1·03)
Q4 25% 18% 0·4 (0·23–0·68) 0·41 (0·19–0·89)
X2 trend (P-value) · · 0·000 0·033
X2Heterogeneity (3df) (P-value) · · 0·005 0·121
B CIDRα2·9 CD36 PfEMP1_IT4var45
Q1 25% 25% Ref· Ref.
Q2 25% 32% 0·99 (0·61–1·59) 1·37 (0·76–2·46)
Q3 25% 21% 0·62 (0·37–1·05) 1·36 (0·65–2·82)
Q4 25% 22% 0·66 (0·39–1·12) 1·8 (0·8–4·04)
X2 trend (P-value) · · 0·041 0·189
X2Heterogeneity (3df) (P-value) · · 0·129 0·521
B CIDRα2·9 CD36 PfEMP1_IT4var61
Q1 25% 22% Ref· –
Q2 25% 24% 0·97 (0·57–1·63) –
Q3 25% 24% 0·95 (0·56–1·61) –
Q4 25% 30% 1·41 (0·83–2·39) –
X2 trend (P-value) · · 0·183 –
X2Heterogeneity (3df) (P-value) · · 0·310 –
– – – GLURP_R2
Q1 25% 26% Ref· –
Q2 25% 27% 0·88 (0·55–1·42) –
Q3 25% 24% 0·79 (0·48–1·3) –
Q4 25% 23% 0·66 (0·39–1·09) –
X2 trend (P-value) · · 0·096 –
X2Heterogeneity (3df) (P-value) · · 0·420 –
– – – SE36
Q1 25% 20% Ref· Ref.
Q2 25% 21% 1·12 (0·67–1·9) 1·14 (0·65–2)
Q3 25% 27% 1·47 (0·88–2·43) 1·69 (0·98–2·92)
Q4 25% 32% 1·61 (0·98–2·65) 1·92 (1·1–3·36)
X2 trend (P-value) · · 0·032 0·007
X2Heterogeneity (3df) (P-value) · · 0·190 0·054
– – – 6NANP
Q1 25% 22% Ref· Ref.
Q2 25% 34% 1·23 (0·75–2) 0·94 (0·52–1·68)
Q3 25% 28% 1·09 (0·65–1·83) 0·94 (0·49–1·82)
Q4 25% 17% 0·62 (0·35–1·12) 0·54 (0·26–1·15)
X2 trend (P-value) · · 0·084 0·109
X2Heterogeneity (3df) (P-value) · · 0·056 0·199
a Case-control associationswith IgG reactivity tomalaria antigens determined using logistic regression· IgG reactivity is coded as quartiles 0, 1, 2, and 3 estimated fromMFI values in the
country-speciﬁc controls, and the results are controlled for age group, proximity to water, rural urban status, and plate number in Uganda (minimally adjusted models).
b Case-control associations with IgG reactivity to malaria antigens determined using logistic regression with additional adjustment for antigens associatedwith eBL at a p b 0·05 based
on trend or heterogeneity analysis in the minimally adjusted models.
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sion of inhibitory receptors, such as RIFINs, to dampen detrimental B-
cell-mediated immune response and render the host more hospitable
to parasites [32]. Finally, co-infections, especially Epstein-Barr virus
(EBV), which has been reported to induce suppression of humoral im-
munity tomalaria [33],may down-modulatemalaria-related inﬂamma-
tion in a manner beneﬁcial to the host, parasite and virus.
We considered alternative explanations, includingwhether eBL cases
were exposed to malaria to the same degree as the controls, or whether
eBL is associated with impaired humoral immunity. While the case-
control design does not allow assessment of temporality of the associa-
tions, it is an efﬁcient design, and we closely matched the eBL cases and
controls geographically. We found that the Ugandan eBL cases were
more likely than their matched controls to be exposed to malaria, based
on enrolment during the wet season and beingmore likely to report re-
cent (one year before onset of symptoms) outpatient (22% versus 9%)
and inpatient (24% versus 19%) malaria treatment. Whether eBL is asso-
ciatedwithdecrease inplasma IgG reactivity, due to increased catabolism
or loss in urine, cannot be excluded. There are multiple reports of lower
levels of total and malaria-speciﬁc IgG, IgM and IgA antibodies in eBL
cases than controls in Uganda, Ghana, and Nigeria, and lower IgG re-
sponse to measles in Uganda (reviewed in [14]). However, the reported
lower levels of IgG, IgA, and IgM did not change when the cases were
monitored before treatment and through long-term remission in
Uganda and Ghana. We also note that eBL cases are more likely to havehigher IgG reactivity to EBV capsid antigens [28] and to othermalaria an-
tigens (Pf whole schizont extract and HRP-2 protein [14]). Behavior
change after eBLdiagnosis, such as hospitalizations associatedwith treat-
ment formalaria ormosquito bed-net usagemay reduce exposure toma-
laria and loss of immunologicalmemory response, but this explanation is
not supportedbyourﬁnding that recent inpatient andoutpatientmalaria
treatment was less frequent in eBL cases than controls; overall, all biases
cannot be eliminated. However, we adjusted for other factors, including
age, geographical variables (season, rural-urban status, proximity of vil-
lage towater) andsickle cell trait,malaria antigenemia in sensitivity anal-
yses, to increase thevalidity of ourﬁndings [4]. The strengths of this study
are the use of a broad panel of antigen targets of immunity to malaria
representing allmain functional types of PfEMP1 variants and the utiliza-
tion of well-matched samples from two geographically distinct studies.
The use of samples from two populations is a strength because the
consistent ﬁndings, despite apparent unexplained differences in sample
variability (Ghana samples seemed to have less variability than the
Ugandan samples), suggest that the observed patterns are likely
valid. Our ﬁndings for SE36, a recombinant protein comprising the
N-terminal of SERA5, conﬂict with those from our previous study in
Ghana in which antibody levels to SE36 was found to be lower in eBL
cases compared to controls [14]. This might be due to differences in the
antigens used (Pf Honduras 1 versus 3D7 Pf).
In conclusion,we found signiﬁcant inverse associations between eBL
and a narrower breadth and intensity of reactivity to PfEMP1-derived
367A. Derkach et al. / EBioMedicine 39 (2019) 358–368antigens in Ghana and Uganda. These ﬁndings suggest that attenuated
humoral immunity to Pfmay be an eBL risk factor for children who re-
main exposed to malaria.Data sharing
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